Your Nervous System Is Running Your Business — Whether You Realize It or Not
There's a specific kind of tired that doesn't respond to sleep.
You know the type: the kind that shows up as a slight lag before you respond in a conversation, a flicker of irritability at the wrong moment, a decision that felt fine until it didn't. You're not burned out in any way you could point to on paper. Your calendar is managed. Your diet is reasonable. You exercise. By every external measure, you're operating well.
But something in the background is running hot — a low-level reactivity that blunts the sharpest edges of your thinking, a nervous system still calibrated for pressure rather than presence. You've adapted to it so completely that it feels like your baseline. It probably isn't.
This piece is about that gap — the one between how well you think you're operating and how well your neurobiology will actually allow. And it's about a body of research that suggests that gap can be closed, more completely and more durably than most people expect.
The Nervous System as Infrastructure
We talk about attention, resilience, and clear judgment as if they were character traits — things you either have or develop through discipline. In reality, they're largely downstream of nervous system function. Your ability to stay regulated under pressure, to read a room accurately, to access creative problem-solving when stakes are high — these capacities sit on a biological substrate that can be in better or worse condition.
When that substrate is carrying the accumulated weight of chronic stress, unprocessed experiences, or dysregulated threat response patterns, performance degrades in ways that are easy to rationalize and hard to measure.
You become less able to tolerate ambiguity. You optimize for certainty over accuracy. You mistake urgency for importance. You respond to your team from a place of activation rather than attunement. The decisions still get made. The work still gets done. But the quality of both is quietly compromised.
This is not a personal failing. It's physiology.
What "Recalibration" Actually Means
The term nervous system recalibration sounds abstract, but it has a concrete neurobiological meaning. It refers to the process by which a dysregulated autonomic nervous system — one stuck in patterns of hypervigilance, emotional blunting, or reactive threat response — returns to a more flexible baseline state.
A well-functioning nervous system is not a calm one. It's a responsive one. It moves fluidly between states of activation and rest, between focus and open awareness. It threat-detects accurately rather than chronically. It recovers quickly from stressors rather than staying elevated long after the stressor has passed.
The clinical term for that flexibility is vagal tone. The experiential term for it is presence.
When your nervous system has sufficient flexibility, you show up differently in every domain that matters — in the quality of your attention during a difficult meeting, in the emotional bandwidth you bring to your family at the end of a long day, in the decision-making clarity you access under genuine pressure rather than manufactured urgency.
The Evidence That Quantifies This
In 2024, researchers at Stanford University published a landmark study in Nature Medicine examining the effects of ibogaine — a plant-derived alkaloid used in West African Bwiti tradition — combined with magnesium therapy, on a cohort of 30 Special Operations Forces veterans with traumatic brain injuries and significant psychiatric burden.
The results were unusual enough to warrant close reading.
At one month post-treatment, the study's primary functioning measure — the World Health Organization Disability Assessment Schedule 2.0 (WHODAS-2.0) — showed an effect size of Cohen's d = 2.20. For context, an effect size above 0.8 is considered "large" in clinical research. An effect size of 2.20 is roughly unprecedented in the psychiatric literature for a single-session intervention.
Improvements in PTSD symptoms reached d = 2.54. Depression scores hit d = 2.80. Anxiety measures came in at d = 2.13. All statistically significant, all sustained at the one-month follow-up. 1
But the more granular cognitive data may be the most relevant here. Neuropsychological testing showed statistically significant improvements in processing speed (d = 1.34 at one month), cognitive inhibition (d = 1.22), cognitive flexibility (d = 0.74), working memory (d = 0.31), and problem-solving (d = 0.44). Sustained attentional accuracy improved markedly, with participants showing a shift toward prioritizing accuracy over speed — a pattern the researchers described as consistent with "reduced impulsivity." 1
These are not abstract wellness metrics. They are the cognitive substrate of good judgment.
What These Numbers Mean in Practice
Processing speed affects how quickly you synthesize incoming information. Cognitive flexibility determines how well you update your model of a situation when the situation changes. Cognitive inhibition is your capacity to suppress reactive responses and not act on the first signal your nervous system generates.
Together, these capacities determine how much of your intelligence actually reaches the surface in high-stakes moments. A nervous system running under load — chronically activated, poorly regulated, carrying unresolved stress residue — suppresses access to all three. The intelligence is still there. The neural architecture just can't access it cleanly.
Why Ibogaine Does This When Other Interventions Don't
Ibogaine is not a sedative or an anxiolytic. It does not simply quiet the nervous system down. What the research suggests it does is structurally different: it appears to reset certain patterned states in the nervous system by acting on multiple neurotransmitter systems simultaneously, while also triggering the release of neurotrophic factors that promote neural repair and plasticity.
Ibogaine and its primary metabolite, noribogaine, have been shown to upregulate brain-derived neurotrophic factor (BDNF) and glial cell-derived neurotrophic factor (GDNF) — proteins essential to synaptic plasticity, neuronal survival, and the capacity for new learning.2 Noribogaine has also been shown to promote neuritogenesis and has been classified as a "psychoplastogen" — a compound capable of physically increasing the complexity of dendritic architecture in a manner comparable to ketamine.3
This is the mechanism that likely underlies the durability of the effects observed in the Stanford study. Ibogaine doesn't just interrupt a dysregulated state; it appears to provide the neurochemical conditions for that state to be structurally replaced.
Additionally, the Stanford sleep data from the same cohort showed significant independent improvements in sleep quality and insomnia severity after treatment — improvements that were not fully explained by reductions in PTSD symptoms alone, suggesting a direct regulatory effect on sleep architecture. 4
Sleep, of course, is the single most powerful lever in cognitive performance. And sleep disruption is one of the most reliable consequences of a chronically activated nervous system.
The Compounding Logic of Neurological Health
Here is the frame that makes this relevant beyond a clinical conversation.
Every professional decision, every relational interaction, every moment of sustained focus or creative insight runs through your nervous system. The quality of that infrastructure determines, more than most people acknowledge, the quality of the output. And unlike skills, which can be sharpened incrementally, neurological function can plateau — or degrade — in ways that skill practice cannot reverse.
The people who are most affected by nervous system dysregulation are often the ones who have pushed hardest and adapted most successfully to high-load environments. The adaptation is real. The cost of the adaptation is also real. And the adaptation itself can become the obstacle — because a nervous system calibrated for sustained pressure does not naturally shift toward the wide-angle awareness that drives genuine strategic clarity, deep relational attunement, or the kind of regenerative rest that compounds over time.
Recalibrating that system is not a pause in performance. It's a structural upgrade to the platform that performance runs on.
What changes after effective neurological recalibration is not personality or competence. It's the signal-to-noise ratio. The same intelligence, the same experience, the same relationships — accessed through a nervous system that is no longer working against you.
Practical Considerations: What This Looks Like at Nomena
At Nomena, ibogaine treatment is conducted under full medical supervision, with comprehensive cardiac screening and monitoring — including cardiac telemetry during the session — and individualized pre- and post-treatment support protocols.
Ibogaine carries real physiological risks if administered without proper medical vetting, primarily cardiac in nature. These risks can be effectively managed with rigorous screening, appropriate dosing, and magnesium co-administration, as demonstrated in the Stanford protocol.1 Our team takes this responsibility seriously.
The ibogaine experience itself typically lasts 24 to 36 hours, with a period of integration following. Most clients describe the cognitive and regulatory changes as becoming fully apparent in the weeks that follow, not immediately — consistent with the timeline shown in the research.
Nomena is located in Southeast Asia, offering a setting designed for deep rest and integration, away from the environments and cues that maintain existing neurological patterns.
Frequently Asked Questions
Is ibogaine treatment appropriate for people who are not dealing with addiction?
Yes. While ibogaine has the longest research history in the context of substance use disorders, a growing body of evidence — including the Stanford MISTIC study — demonstrates meaningful effects on functioning, cognitive performance, PTSD, depression, and anxiety independent of addiction. Many of Nomena's clients are primarily seeking neurological recalibration, better regulation, and improved cognitive and emotional function, rather than addiction treatment.
How does ibogaine treatment compare to other interventions like therapy, ketamine, or psilocybin?
Each of these interventions has a distinct mechanism and a distinct evidence base. Ibogaine is unusual in that it appears to produce lasting changes through a single or small number of sessions, acts on a broader range of neurotransmitter systems simultaneously, and has demonstrated effect sizes in the published clinical literature that exceed those typically reported for other psychedelic-assisted interventions. It is also a more medically complex intervention with real cardiac risks, which is why proper screening and medical supervision are non-negotiable.
What does the "integration" period after treatment involve?
Integration refers to the weeks following treatment when the neuroplastic window opened by ibogaine is most active. This is the period during which new patterns of thinking, behavior, and regulation consolidate most readily. At Nomena, we provide structured integration support, and we recommend that clients arrange reduced external load — fewer high-pressure obligations, more deliberate rest — in the weeks following treatment where possible.
Is ibogaine legal?
Ibogaine's legal status varies by country. It is unscheduled or legally administered in several jurisdictions, including the country where Nomena operates. We recommend all prospective clients consult the relevant legal frameworks for their home country regarding treatment travel. Ibogaine is currently unscheduled in many Southeast Asian countries and legally administered under medical supervision at licensed facilities.
How do I know if I'm a good candidate?
The single most important variable is cardiovascular health. Certain cardiac conditions and specific medications — particularly QT-prolonging drugs — are contraindications for ibogaine treatment. A thorough pre-treatment screening process, including electrocardiogram (ECG), cardiac history, and full medication review, is required for all Nomena applicants. Beyond cardiac clearance, we assess overall health, current medications, and personal goals to determine whether ibogaine is appropriate and, if so, how to structure the protocol for the best outcome.
Work With Nomena
If you're reading this and something has resonated — if you recognize the gap between how you're functioning and how your neurobiology might allow you to function — we'd welcome a conversation.
Nomena is an ibogaine treatment center located in Southeast Asia, operating under full medical supervision with individualized protocols and comprehensive integration support. We work with a small number of clients at a time, and we take the screening process seriously, because we're committed to outcomes, not volume.
To begin the intake and screening process, or to speak with a member of our clinical team, visit [nomena.com] or contact us directly.
References
1: Cherian, K.N., Keynan, J.N., Anker, L., Faerman, A., Brown, R.E., Shamma, A., Keynan, O., Coetzee, J.P., Batail, J.M., Phillips, A., Bassano, N.J., Sahlem, G.L., Inzunza, J., Millar, T., Dickinson, J., Rolle, C.E., Keller, J., Adamson, M., Kratter, I.H., & Williams, N.R. (2024). Magnesium-ibogaine therapy in veterans with traumatic brain injuries. Nature Medicine, 30, 373–381. [https://doi.org/10.1038/s41591-023-02705-w]
2: Marton, S., González, B., Rodríguez-Bottero, S., Miquel, E., Martínez-Palma, L., Pazos, M., Prieto, J.P., Rodríguez, P., Sames, D., Seoane, G., Scorza, C., Cassina, P., & Carrera, I. (2019). Ibogaine administration modifies GDNF and BDNF expression in brain regions involved in mesocorticolimbic and nigral dopaminergic circuits. Frontiers in Pharmacology, 10, 193. [https://doi.org/10.3389/fphar.2019.00193]
3: González Espejito, F., Esteban Rodríguez, L., Pedrero Pérez, E.J., Dickinson, J., Kohek, M., Guimaraes dos Santos, R., Hallak, J., Alcázar-Córcoles, M.Á., Morgan, B.L., & Bouso, J.C. (2025). The Ibogaine Experience Scale (IES): Development and psychometric properties of a multidimensional measure of ibogaine's subjective effects. PLOS One, 20(10), e0333296. [https://doi.org/10.1371/journal.pone.0333296]
4: Faerman, A., Anker, L., Cherian, K., Brown, R., & Williams, N. (2023). Ibogaine treatment in combat veterans significantly improves sleep, beyond alleviating posttraumatic stress disorder symptoms. SLEEP, 46(Supplement 1), A292. Abstract citation ID: zsad077.0665.